RxDoctor Payments Data

Allison Douglas-Clements, NP

Psychiatric/Mental Health · Midlothian, VANPI 1649391418

Payments from drug & device makers

$6,116in general payments, 2019–2025

Across 340 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$957
  • Neurocrine Biosciences, Inc.$821
  • Johnson & Johnson$763
  • Otsuka America Pharmaceutical, Inc.$421
  • Takeda Pharmaceuticals U.S.A., Inc.$361
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,05599%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,116 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$14,428
Medicare patients
18
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate21$38,136
RexultiBrexpiprazole11$16,928
Aripiprazole32$2,930
Quetiapine Fumarate96$2,205
Venlafaxine Hcl ErVenlafaxine Hcl38$1,573
Duloxetine Hcl26$1,412
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,212
Haloperidol12$1,149
Temazepam22$951
Trazodone Hcl43$781
Lamotrigine55$734
Bupropion XlBupropion Hcl63$715
Buspirone Hcl50$699
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28$654
Olanzapine OdtOlanzapine13$514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,217$38,13621 claims
Otsuka America Pharmaceutical, Inc.Rexulti$421$16,92811 claims
Almatica Pharma LLCSertraline Hcl$71$18036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →